Please ensure Javascript is enabled for purposes of website accessibility

Why Lucira Health Stock Is Plunging Today

By Prosper Junior Bakiny - Apr 13, 2021 at 2:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This analyst thinks the company's stock performance will trail that of the market.

What happened?

After rising sharply on Monday, shares of medical technology company Lucira Health (LHDX 13.92%) are going in the opposite direction on Tuesday. The company's stock dropped by as much as 22.6% today and was down by 18.5% as of 1:51 p.m. EDT. Lucira Health did not report any news today, but we can attribute its woes on the stock market to bearish commentary from a Wall Street analyst.

So what

Bank of America analyst Derik de Bruin downgraded Lucira Health's stock to underperform from buy. The analyst also gave the stock a price target of $9. Shares of the company closed yesterday's trading session at $10.91. To understand the reasons behind de Bruin's lack of enthusiasm regarding Lucira Health's prospects, a little bit of context is needed. Yesterday, the company reported that the U.S. Food and Drug Administration (FDA) had granted an Emergency Use Authorization (EUA) to its Lucira Check It COVID-19 test kit for over-the-counter (OTC) sale.

Man holding his head looking at a downward-bound graph on a board.

Image source: Getty Images.

This bit of news seemed like a positive development for Lucira Health as the OTC availability of its coronavirus test kit will almost certainly increase its accessibility to the general public and could positively impact its sales. However, the healthcare company also provided less than impressive preliminary first-quarter results. Lucira Health expects revenue between $4 million and $4.5 million, which is well below the current consensus analyst estimate of $9.42 million.

Bank of America's forecast was for the company to report $12.5 million in revenue during the first quarter, and de Bruin believes that this (likely) top-line miss will be due to a lack of demand for the company's COVID-19 test kit. Also, the COVID-19 testing market as a whole is taking a hit due to the rollout of vaccines for the disease, which further complicates matters for Lucira Health.

Now what

Lucira Health is set to report its first-quarter earnings on May 13. The company's financial results will tell investors more regarding the impact the recent EUA will have on its overall performance. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lucira Health, Inc. Stock Quote
Lucira Health, Inc.
LHDX
$2.21 (13.92%) $0.27
Bank of America Corporation Stock Quote
Bank of America Corporation
BAC
$30.98 (-0.83%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.